Skip to main content

Búsqueda de biomarcadores (inmunológicos y/o celulares) predictivos de respuesta virológica o de control de la infección en la hepatitis crónica D.

PI23/01065

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de I+D+i en Salud
Call year 2023
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO DE INVESTIGACION VALLE DE HEBRON
Execution centre INSTITUTO DE INVESTIGACION HOSPITAL UNIVERSITARIO VALLE DE HEBRON (VHIR)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Enhancing linkage to care for hepatitis B, D, and C patients, A retrospective-prospective study

  • Vargas-Accarino, Elena|||0000-0002-2521-0368
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Palom, Adriana|||0000-0002-0130-1302
  • Feliu-Prius, Anna|||0000-0002-6835-1718
  • Martínez-Campreciós, Joan|||0000-0002-8899-8447
  • Barreira-Diaz, Ana|||0000-0002-4368-8939
  • Romero-Vico, Judith
  • Ruiz Cobo, Juan Carlos|||0000-0003-2239-4939
  • Llaneras Artigues, Jordi|||0000-0001-9011-3954
  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Esteban, Rafael|||0000-0001-5280-392X
  • Buti, Maria|||0000-0002-0732-3078
Background: The WHO has set a goal to decrease viral hepatitis-related fatalities by 65% by 2030. Aims: To locate and retrieve to care all individuals diagnosed with hepatitis B, D or C, and investigate why they were not linked to appropriate medical management. Methods: We conducted a retrospective-prospective search for patients with hepatitis B, D or C virus (HBV, HDV and HCV) infection in the central laboratory database of the Barcelona northern health area (catchment population, 450,000). We reviewed records and contacted candidates for retrieval who were offered a specialist medical visit. Results: We reviewed records of 3731 patients with viral hepatitis (January 2019-December 2022): 1763 HBsAg+, 69 anti-HDV+ and 1899 HCV-RNA+. Among these, 644 (37%) HBV, 20 (29%) HDV and 1116 (56%) HCV patients were not currently linked to care. The proportion of patients receiving appropriate care was higher in HBV and HDV (p < 0.0001), and a higher percentage of unlinked hepatitis C patients had low life expectancy/comorbidities (39%; p < 0.0001). After implementing the linkage strategy, 254 HBV, 16 HDV and 54 HCV patients were successfully reintegrated into care. Among 1780 patients requiring linkage, 638 (35.8%) had moved to another health area or were missing essential contact data. Conclusions: Among patients with viral hepatitis who required appropriate specialist care and were eligible for contact, 64% with HBV, 100% with HDV and 27% with HCV were successfully reintegrated into care. Overall, 324 (47.2%) eligible patients were linked to care, indicating the success of this strategy.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Deep Sequencing Reveals Dual Evolution of SARS-CoV-2, Insights Into Defective Genomes From Wuhan-Hu-1 Variants to Omicron Subvariants

  • Campos, Carolina|||0000-0002-0132-7027
  • Ibañez Lligoña, Marta|||0000-0003-3428-2168
  • Colomer Castell, Sergi|||0000-0002-0307-7455
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Garcia-Cehic, D.|||0000-0002-0009-038X
  • Andrés, Cristina|||0000-0002-3200-0895
  • Piñana, Maria|||0000-0002-4766-2613
  • González Sánchez, Alejandra|||0000-0002-1809-3415
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Esperalba, Juliana|||0000-0003-1326-1341
  • Saubi, Narcis|||0000-0001-5493-1044
  • Cortese, Maria Francesca|||0000-0002-4318-532X
  • Tabernero, David|||0000-0002-1146-4084
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Ferrer Costa, Roser|||0000-0002-8925-3172
  • Esteban Mur, Juan Ignacio|||0000-0001-5085-917X
  • Kakze-van der Honing, Renate W.
  • Kampfraath, Andries A.
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • van der Poel, Wim H. M.
  • Pumarola Suñé, Tomàs|||0000-0002-5171-7461
  • Antón Pagarolas, Andrés, 1976-|||0000-0002-1476-0815
  • Quer, Josep|||0000-0003-0014-084X
SARS-CoV-2 has evolved from early variants dominating the first (B.1.5, B.1.1) and second (B.1.177) pandemic waves, which exhibited a higher frequency of minority mutants with deletions leading to Defective Viral Genomes (DVGs) in the spike region near the S1/S2 cleavage site than the Alpha, Beta, and Delta variants. The emergence of Omicron has significantly altered the dominant variant profile, with Omicron subvariants now representing 100% of circulating viruses. To monitor the evolution and adaptation of Omicron in the human population, a deep-sequencing study was performed in RNA samples of BA.1, BA.1.1, BA.2, BA.5, BQ.1.1, XBB.1.5 and BA.2.86 Omicron subvariants. The findings reveal two occurrences of similar evolutionary patterns within SARS-CoV-2 characterized by a shift from a significant to a very low production of DVGs. This event suggests that DVGs might play a role in the virus's spread and adaptation for persistence in infected humans.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Beyond Risk Factors, Rethinking Hepatitis B and Hepatitis C Screening in Primary Care

  • Vargas-Accarino, Elena|||0000-0002-2521-0368
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Úbeda, María Asunción
  • Valls, Imma
  • Ventosa, Carla
  • García, Núria
  • Arcusa, Ingrid
  • Monserrate, Elena
  • de Diego, Eva
  • Selvi, Marta
  • Palom, Adriana|||0000-0002-0130-1302
  • Llorens, Marina
  • Santos, Maria
  • Romero-Vico, Judit
  • Dalfó Pibernat, Artur|||0000-0002-2539-3715
  • Ruiz Cobo, Juan Carlos|||0000-0003-2239-4939
  • Pallares, Ester
  • Buti, Maria|||0000-0002-0732-3078
Most international guidelines recommend screening for hepatitis B virus (HBV) and hepatitis C virus (HCV) only for individuals with risk factors or elevated ALT levels. However, this approach may not suffice to eradicate viral hepatitis. This study evaluates the application of EASL HBV and HCV screening guidelines in primary care centres (PCCs). The study included two components: (1) A retrospective review (January 2021-March 2023) of microbiology data to determine testing rates, analyse clinical characteristics, and assess management; and (2) A prospective intervention (March-April 2024) involving HBV and HCV screening and risk factor surveys for all adults attending two PCCs for blood collection. In the retrospective analysis of 90 170 patients, HBV and HCV screening rates were 16% and 10%, respectively. Among HBsAg-positive patients (n = 84 (0.5%)), 67% lacked risk factors or elevated ALT. Among anti-HCV-positive (n = 277 (3%)) and HCV RNA-positive (n = 45 (0.5%)) patients, 54% and 46% respectively lacked these indicators. In the prospective study of 1030 patients (mean age 55, 39.6% men, 73% Spanish), anti-HCV was detected in 1.16% of cases (HCV RNA in 0.19%). Of these, 67% lacked risk factors or elevated ALT. No HBsAg-positive cases were identified, and hepatitis B vaccination status was uncertain for 50% of patients. Risk factor-based screening for HBV and HCV in primary care is a suboptimal approach. More than half of the patients testing positive lacked identifiable risk factors or elevated ALT levels. Universal one-time screening for all adults could address these limitations and significantly advance viral hepatitis elimination efforts.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Enhancing linkage to care for hepatitis B, D, and C patients: A retrospective-prospective study

  • Barreira Diaz, Ana
  • Romero-Vico, Judit
  • Llaneras Artigues, Jordi
  • esteban, rafael
  • Vargas-Accarino, Elena
  • Rando Segura, Ariadna
  • Palom, Adriana
  • Feliu-Prius, Anna
  • Martínez-Campreciós, Joan
  • Ruiz Cobo, Juan Carlos
  • Riveiro-Barciela, Mar
  • RODRIGUEZ-FRIAS, FRANCISCO
  • Buti Ferret, Maria
Patient care; Hepatitis B; Hepatitis D, Atención a los pacientes; Hepatitis B; Hepatitis D, Atenció als pacients; Hepatitis B; Hepatitis D, Background The WHO has set a goal to decrease viral hepatitis-related fatalities by 65% by 2030. Aims To locate and retrieve to care all individuals diagnosed with hepatitis B, D or C, and investigate why they were not linked to appropriate medical management. Methods We conducted a retrospective-prospective search for patients with hepatitis B, D or C virus (HBV, HDV and HCV) infection in the central laboratory database of the Barcelona northern health area (catchment population, 450,000). We reviewed records and contacted candidates for retrieval who were offered a specialist medical visit. Results We reviewed records of 3731 patients with viral hepatitis (January 2019–December 2022): 1763 HBsAg+, 69 anti-HDV+ and 1899 HCV-RNA+. Among these, 644 (37%) HBV, 20 (29%) HDV and 1116 (56%) HCV patients were not currently linked to care. The proportion of patients receiving appropriate care was higher in HBV and HDV (p < 0.0001), and a higher percentage of unlinked hepatitis C patients had low life expectancy/comorbidities (39%; p < 0.0001). After implementing the linkage strategy, 254 HBV, 16 HDV and 54 HCV patients were successfully reintegrated into care. Among 1780 patients requiring linkage, 638 (35.8%) had moved to another health area or were missing essential contact data. Conclusions Among patients with viral hepatitis who required appropriate specialist care and were eligible for contact, 64% with HBV, 100% with HDV and 27% with HCV were successfully reintegrated into care. Overall, 324 (47.2%) eligible patients were linked to care, indicating the success of this strategy., This work was supported by an unrestricted grant from Gilead Sciences and by Instituto de Salud Carlos III (ISCIII) (PI23/01065).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

In-Host Flat-like Quasispecies: Characterization Methods and Clinical Implications

  • Gregori Font, Josep
  • Colomer-Castell, Sergi
  • Ibañez Lligoña, Marta
  • Garcia-Cehic, Damir
  • Campos, Carolina
  • Riveiro-Barciela, Mar
  • Piñana, María
  • González-Sánchez, Alejandra
  • RODRIGUEZ-FRIAS, FRANCISCO
  • Cortese, Maria Francesca
  • Tabernero, David
  • Rando Segura, Ariadna
  • Pumarola Suñe, Tomàs
  • Esteban Mur, Juan Ignacio
  • QUER, JOSEP
  • Buti Ferret, Maria
  • Antón Pagarolas, Andrés
  • Andrés Vergés, Cristina
Cuasiespecies; Mutágenos; Mutaciones, Quasispecies; Mutagens; Mutations, Quasiespècie; Mutàgens; Mutacions, The repeated failure to treat patients chronically infected with hepatitis E (HEV) and C (HCV) viruses, despite the absence of resistance-associated substitutions (RAS), particularly in response to prolonged treatments with the mutagenic agents of HEV, suggests that quasispecies structure may play a crucial role beyond single point mutations. Quasispecies structured in a flat-like manner (referred to as flat-like) are considered to possess high average fitness, occupy a significant fraction of the functional genetic space of the virus, and exhibit a high capacity to evade specific or mutagenic treatments. In this paper, we studied HEV and HCV samples using high-depth next-generation sequencing (NGS), with indices scoring the different properties describing flat-like quasispecies. The significance of these indices was demonstrated by comparing the values obtained from these samples with those from acute infections caused by respiratory viruses (betacoronaviruses, enterovirus, respiratory syncytial viruses, and metapneumovirus). Our results revealed that flat-like quasispecies in HEV and HCV chronic infections without RAS are characterized by numerous low-frequency haplotypes with no dominant one. Surprisingly, these low-frequency haplotypes (at the nucleotide level) exhibited a high level of synonymity, resulting in much lower diversity at the phenotypic level. Currently, clinical approaches for managing flat-like quasispecies are lacking. Here, we propose methods to identifying flat-like quasispecies, which represents an essential initial step towards exploring alternative treatment protocols for viruses resistant to conventional therapies., This study was partially supported by Centro para el Desarrollo Tecnológico Industrial (CDTI) from the Spanish Ministry of Economy and Business, grant number IDI-20200297; Grant PID2021-126447OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by ERDF A way of making Europe; Fondo de Investigación Sanitaria, Ministerio Español de Economía y Competitividad (grants FIS PI19/00301, PI22/00258, PI22/00023 and PI23/01065); CIBER—Consorcio Centro de Investigación Biomédica en Red—(CIBERINFEC, ISCIII—CIBER de Enfermedades Infecciosas & CIBEREHD, ISCIII. CIBER de Enfermedades Hepáticas y Digestivas), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea—NextGenerationEU; S.C.-C received support from the Spanish Ministry of Education grant FPU21/04150. M.I.-L. received the support of a fellowship from ”La Caixa” Foundation (ID 100010434), whose code is “LCF/BQ/DR23/12000020”. C.C. has received a fellowship from VHIR.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Beyond Risk Factors: Rethinking Hepatitis B and Hepatitis C Screening in Primary Care

  • Rando Segura, Ariadna
  • Ubeda, Maria
  • Valls, Imma
  • Ventosa, Carla
  • García Hernandez, Nuria
  • Romero Vico, judit
  • Vargas-Accarino, Elena
  • Palom, Adriana
  • Ruiz Cobo, Juan Carlos
  • Buti Ferret, Maria
hepatitis B; hepatitis C; Primary care, Hepatitis B; Hepatitis C; Atención primaria, hepatitis B; Hepatitis C; Atenció primària, Introduction Most international guidelines recommend screening for hepatitis B virus (HBV) and hepatitis C virus (HCV) only for individuals with risk factors or elevated ALT levels. However, this approach may not suffice to eradicate viral hepatitis. This study evaluates the application of EASL HBV and HCV screening guidelines in primary care centres (PCCs). Methods The study included two components: (1) A retrospective review (January 2021–March 2023) of microbiology data to determine testing rates, analyse clinical characteristics, and assess management; and (2) A prospective intervention (March–April 2024) involving HBV and HCV screening and risk factor surveys for all adults attending two PCCs for blood collection. Results In the retrospective analysis of 90 170 patients, HBV and HCV screening rates were 16% and 10%, respectively. Among HBsAg-positive patients (n = 84 (0.5%)), 67% lacked risk factors or elevated ALT. Among anti-HCV-positive (n = 277 (3%)) and HCV RNA-positive (n = 45 (0.5%)) patients, 54% and 46% respectively lacked these indicators. In the prospective study of 1030 patients (mean age 55, 39.6% men, 73% Spanish), anti-HCV was detected in 1.16% of cases (HCV RNA in 0.19%). Of these, 67% lacked risk factors or elevated ALT. No HBsAg-positive cases were identified, and hepatitis B vaccination status was uncertain for 50% of patients. Conclusion Risk factor-based screening for HBV and HCV in primary care is a suboptimal approach. More than half of the patients testing positive lacked identifiable risk factors or elevated ALT levels. Universal one-time screening for all adults could address these limitations and significantly advance viral hepatitis elimination efforts., This research was partially funded by Instituto de Salud Carlos III (ISCIII) (PI23/01065).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

In-Host Flat-like Quasispecies, Characterization Methods and Clinical Implications

  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Colomer Castell, Sergi|||0000-0002-0307-7455
  • Ibañez Lligoña, Marta|||0000-0003-3428-2168
  • Garcia-Cehic, D.|||0000-0002-0009-038X
  • Campos, Carolina|||0000-0002-0132-7027
  • Buti, Maria|||0000-0002-0732-3078
  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Andrés, Cristina|||0000-0002-3200-0895
  • Piñana, Maria|||0000-0002-4766-2613
  • González Sánchez, Alejandra|||0000-0002-1809-3415
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Cortese, Maria Francesca|||0000-0002-4318-532X
  • Tabernero, David|||0000-0002-1146-4084
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Pumarola Suñé, Tomàs|||0000-0002-5171-7461
  • Esteban Mur, Juan Ignacio|||0000-0001-5085-917X
  • Antón Pagarolas, Andrés, 1976-|||0000-0002-1476-0815
  • Quer, Josep|||0000-0003-0014-084X
The repeated failure to treat patients chronically infected with hepatitis E (HEV) and C (HCV) viruses, despite the absence of resistance-associated substitutions (RAS), particularly in response to prolonged treatments with the mutagenic agents of HEV, suggests that quasispecies structure may play a crucial role beyond single point mutations. Quasispecies structured in a flat-like manner (referred to as flat-like) are considered to possess high average fitness, occupy a significant fraction of the functional genetic space of the virus, and exhibit a high capacity to evade specific or mutagenic treatments. In this paper, we studied HEV and HCV samples using high-depth next-generation sequencing (NGS), with indices scoring the different properties describing flat-like quasispecies. The significance of these indices was demonstrated by comparing the values obtained from these samples with those from acute infections caused by respiratory viruses (betacoronaviruses, enterovirus, respiratory syncytial viruses, and metapneumovirus). Our results revealed that flat-like quasispecies in HEV and HCV chronic infections without RAS are characterized by numerous low-frequency haplotypes with no dominant one. Surprisingly, these low-frequency haplotypes (at the nucleotide level) exhibited a high level of synonymity, resulting in much lower diversity at the phenotypic level. Currently, clinical approaches for managing flat-like quasispecies are lacking. Here, we propose methods to identifying flat-like quasispecies, which represents an essential initial step towards exploring alternative treatment protocols for viruses resistant to conventional therapies.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

In-Host Flat-like Quasispecies: Characterization Methods and Clinical Implications

  • Gregori Font, Josep
  • Colomer-Castell, Sergi
  • Ibañez Lligoña, Marta
  • Garcia-Cehic, Damir
  • Campos, Carolina
  • Riveiro-Barciela, Mar
  • Piñana, María
  • González-Sánchez, Alejandra
  • RODRIGUEZ-FRIAS, FRANCISCO
  • Cortese, Maria Francesca
  • Tabernero, David
  • Rando Segura, Ariadna
  • Pumarola Suñe, Tomàs
  • Esteban Mur, Juan Ignacio
  • QUER, JOSEP
  • Buti Ferret, Maria
  • Antón Pagarolas, Andrés
  • Andrés Vergés, Cristina
Cuasiespecies; Mutágenos; Mutaciones, Quasispecies; Mutagens; Mutations, Quasiespècie; Mutàgens; Mutacions, The repeated failure to treat patients chronically infected with hepatitis E (HEV) and C (HCV) viruses, despite the absence of resistance-associated substitutions (RAS), particularly in response to prolonged treatments with the mutagenic agents of HEV, suggests that quasispecies structure may play a crucial role beyond single point mutations. Quasispecies structured in a flat-like manner (referred to as flat-like) are considered to possess high average fitness, occupy a significant fraction of the functional genetic space of the virus, and exhibit a high capacity to evade specific or mutagenic treatments. In this paper, we studied HEV and HCV samples using high-depth next-generation sequencing (NGS), with indices scoring the different properties describing flat-like quasispecies. The significance of these indices was demonstrated by comparing the values obtained from these samples with those from acute infections caused by respiratory viruses (betacoronaviruses, enterovirus, respiratory syncytial viruses, and metapneumovirus). Our results revealed that flat-like quasispecies in HEV and HCV chronic infections without RAS are characterized by numerous low-frequency haplotypes with no dominant one. Surprisingly, these low-frequency haplotypes (at the nucleotide level) exhibited a high level of synonymity, resulting in much lower diversity at the phenotypic level. Currently, clinical approaches for managing flat-like quasispecies are lacking. Here, we propose methods to identifying flat-like quasispecies, which represents an essential initial step towards exploring alternative treatment protocols for viruses resistant to conventional therapies., This study was partially supported by Centro para el Desarrollo Tecnológico Industrial (CDTI) from the Spanish Ministry of Economy and Business, grant number IDI-20200297; Grant PID2021-126447OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by ERDF A way of making Europe; Fondo de Investigación Sanitaria, Ministerio Español de Economía y Competitividad (grants FIS PI19/00301, PI22/00258, PI22/00023 and PI23/01065); CIBER—Consorcio Centro de Investigación Biomédica en Red—(CIBERINFEC, ISCIII—CIBER de Enfermedades Infecciosas & CIBEREHD, ISCIII. CIBER de Enfermedades Hepáticas y Digestivas), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea—NextGenerationEU; S.C.-C received support from the Spanish Ministry of Education grant FPU21/04150. M.I.-L. received the support of a fellowship from ”La Caixa” Foundation (ID 100010434), whose code is “LCF/BQ/DR23/12000020”. C.C. has received a fellowship from VHIR.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Beyond Risk Factors: Rethinking Hepatitis B and Hepatitis C Screening in Primary Care

  • Rando Segura, Ariadna
  • Ubeda, Maria
  • Valls, Imma
  • Ventosa, Carla
  • García Hernandez, Nuria
  • Romero Vico, judit
  • Vargas-Accarino, Elena
  • Palom, Adriana
  • Ruiz Cobo, Juan Carlos
  • Buti Ferret, Maria
hepatitis B; hepatitis C; Primary care, Hepatitis B; Hepatitis C; Atención primaria, hepatitis B; Hepatitis C; Atenció primària, Introduction Most international guidelines recommend screening for hepatitis B virus (HBV) and hepatitis C virus (HCV) only for individuals with risk factors or elevated ALT levels. However, this approach may not suffice to eradicate viral hepatitis. This study evaluates the application of EASL HBV and HCV screening guidelines in primary care centres (PCCs). Methods The study included two components: (1) A retrospective review (January 2021–March 2023) of microbiology data to determine testing rates, analyse clinical characteristics, and assess management; and (2) A prospective intervention (March–April 2024) involving HBV and HCV screening and risk factor surveys for all adults attending two PCCs for blood collection. Results In the retrospective analysis of 90 170 patients, HBV and HCV screening rates were 16% and 10%, respectively. Among HBsAg-positive patients (n = 84 (0.5%)), 67% lacked risk factors or elevated ALT. Among anti-HCV-positive (n = 277 (3%)) and HCV RNA-positive (n = 45 (0.5%)) patients, 54% and 46% respectively lacked these indicators. In the prospective study of 1030 patients (mean age 55, 39.6% men, 73% Spanish), anti-HCV was detected in 1.16% of cases (HCV RNA in 0.19%). Of these, 67% lacked risk factors or elevated ALT. No HBsAg-positive cases were identified, and hepatitis B vaccination status was uncertain for 50% of patients. Conclusion Risk factor-based screening for HBV and HCV in primary care is a suboptimal approach. More than half of the patients testing positive lacked identifiable risk factors or elevated ALT levels. Universal one-time screening for all adults could address these limitations and significantly advance viral hepatitis elimination efforts., This research was partially funded by Instituto de Salud Carlos III (ISCIII) (PI23/01065).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Unveiling pathogens and contaminants: refining metagenomics for clinical diagnostics

  • Garcia-Larroy, Jorgina
  • Antón Pagarolas, Andrés
  • Ibañez Lligoña, Marta
  • Colomer-Castell, Sergi
  • Campos, Carolina
  • González Camuesco, Álvaro
  • Llaurado, Arnau
  • Sánchez-Tejerina, Daniel
  • Rando Segura, Ariadna
  • Andrés Vergés, Cristina
  • Esperalba, Juliana
  • Nadal-Barón, Patricia
  • Ferrer Costa, Roser
  • Cortese, Maria Francesca
  • Tabernero, David
  • Gregori Font, Josep
  • Riveiro-Barciela, Mar
  • Ruiz Cobo, Juan Carlos
  • del Barco Martínez, Ester
  • Buti Ferret, Maria
  • Goya, Maria
  • Juntas Morales, Raúl
  • QUER, JOSEP
Coinfection; Ddiagnostics; Metagenomics, Coinfección; Diagnóstico; Metagenómica, Coinfecció; Diagnòstic; Metagenòmica, Introduction: Shotgun metagenomic sequencing (mNGS), an untargeted approach that sequences all nucleic acids in a sample, has emerged as a powerful tool for pathogen detection and genome characterization. However, its implementation in clinical diagnostics remains limited due to technical challenges such as contamination and reduces sensitivity, especially in low-biomass samples.Methods: We applied mNGS to 144 clinical samples representing chronic infections, acute infections, and respiratory co-infections. To address contamination, we established a framework integrating negative controls, lab-specific contaminant watchlists, and computational filtering. Viral detection performance and genome recovery were assessed across sample types and viral loads.Results: Viral load was shown to be the primary determinant of sensitivity, with reliable recovery achieved only at higher titers. Our framework substantially improved contamination management, reducing false-positive signals and enhancing viral genome recovery. mNGS enabled the detection of clinically relevant co-infections and refined viral classification beyond targeted diagnostics, while also revealing the substantial risk of spurious detections in the absence of contamination-aware workflows.Discussion: These findings define practical sensitivity thresholds for clinical mNGS and underscore the need for contamination-aware workflows, particularly for low-biomass samples, while providing an open-source contaminants watchlist that enhances reliability and utility of clinical metagenomics., The author(s) declared that financial support was received for this work and/or its publication. This study was partially supported by Grants PI22/00258, PI22/00023, and PI23/01065 funded by Instituto de Salud Carlos III (ISCIII), Grant PMPER24/00018 and PID2021-126447OB-I00 under the Ministry of Science, Innovation and Universities of Spain and cofounded by the European Union; and Consorcio Centro de Investigación Biomédica en Red CIBERINFEC and CIBEREHD. MI-L was supported by a fellowship from the “La Caixa” Foundation (ID 100010434) with code “LCF/BQ/DR23/12000020.” SC-C received support from the Spanish Ministry of Education grant FPU21/04150. CC received a predoctoral fellowship from Vall d’Hebron Institute of Research (VHIR).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Enhancing linkage to care for hepatitis B, D, and C patients: A retrospective-prospective study

  • Barreira Diaz, Ana
  • Romero-Vico, Judit
  • Llaneras Artigues, Jordi
  • esteban, rafael
  • Vargas-Accarino, Elena
  • Rando Segura, Ariadna
  • Palom, Adriana
  • Feliu-Prius, Anna
  • Martínez-Campreciós, Joan
  • Ruiz Cobo, Juan Carlos
  • Riveiro-Barciela, Mar
  • RODRIGUEZ-FRIAS, FRANCISCO
  • Buti Ferret, Maria
Patient care; Hepatitis B; Hepatitis D, Atención a los pacientes; Hepatitis B; Hepatitis D, Atenció als pacients; Hepatitis B; Hepatitis D, Background The WHO has set a goal to decrease viral hepatitis-related fatalities by 65% by 2030. Aims To locate and retrieve to care all individuals diagnosed with hepatitis B, D or C, and investigate why they were not linked to appropriate medical management. Methods We conducted a retrospective-prospective search for patients with hepatitis B, D or C virus (HBV, HDV and HCV) infection in the central laboratory database of the Barcelona northern health area (catchment population, 450,000). We reviewed records and contacted candidates for retrieval who were offered a specialist medical visit. Results We reviewed records of 3731 patients with viral hepatitis (January 2019–December 2022): 1763 HBsAg+, 69 anti-HDV+ and 1899 HCV-RNA+. Among these, 644 (37%) HBV, 20 (29%) HDV and 1116 (56%) HCV patients were not currently linked to care. The proportion of patients receiving appropriate care was higher in HBV and HDV (p < 0.0001), and a higher percentage of unlinked hepatitis C patients had low life expectancy/comorbidities (39%; p < 0.0001). After implementing the linkage strategy, 254 HBV, 16 HDV and 54 HCV patients were successfully reintegrated into care. Among 1780 patients requiring linkage, 638 (35.8%) had moved to another health area or were missing essential contact data. Conclusions Among patients with viral hepatitis who required appropriate specialist care and were eligible for contact, 64% with HBV, 100% with HDV and 27% with HCV were successfully reintegrated into care. Overall, 324 (47.2%) eligible patients were linked to care, indicating the success of this strategy., This work was supported by an unrestricted grant from Gilead Sciences and by Instituto de Salud Carlos III (ISCIII) (PI23/01065).